We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+23.65%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.28B
AUM Growth
+$464M
Cap. Flow
-$292M
Cap. Flow %
-5.53%
Top 10 Hldgs %
49.47%
Holding
185
New
37
Increased
47
Reduced
83
Closed
9

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$120M
2
FOLD
Amicus Therapeutics
FOLD
+$105M
3
NUVL
Nuvalent
NUVL
+$102M
4
KRYS icon
Krystal Biotech
KRYS
+$86.1M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$75.6M

Top Sells

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$149M
2
INCY icon
Incyte
INCY
+$139M
3
AKRO
Akero Therapeutics
AKRO
+$113M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$109M
5
ARGX icon
argenx
ARGX
+$72.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.71%
2 Technology 0.1%
3 Consumer Discretionary 0.05%
4 Financials 0.03%
5 Communication Services 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDGL icon
101
Madrigal Pharmaceuticals
MDGL
$12.6B
$1.68M 0.03%
2,884
+491
+21% +$251K
EXAS
102
DELISTED
Exact Sciences
EXAS
$1.63M 0.03%
16,062
-236,639
-94% -$19M
CAH icon
103
Cardinal Health
CAH
$53.4B
$1.58M 0.03%
7,669
-8,599
-53% -$1.62M
PTGX icon
104
Protagonist Therapeutics
PTGX
$8.75B
$1.44M 0.03%
16,543
-4,038
-20% -$331K
LH icon
105
Labcorp
LH
$24.3B
$1.42M 0.03%
5,669
-9,396
-62% -$2.5M
PFE icon
106
Pfizer
PFE
$140B
$1.42M 0.03%
56,847
+45,020
+381% +$1.14M
LEGN icon
107
Legend Biotech
LEGN
$4.3B
$1.39M 0.03%
63,971
-21,005
-25% -$602K
GDX icon
108
VanEck Gold Miners ETF
GDX
$23B
$1.33M 0.03%
15,500
-3,000
-16% -$237K
NAMS icon
109
NewAmsterdam Pharma
NAMS
$3.47B
$1.27M 0.02%
36,336
+21,725
+149% +$791K
DGX icon
110
Quest Diagnostics
DGX
$25.1B
$1.26M 0.02%
7,280
-25,735
-78% -$4.69M
CMPS
111
Compass Pathways
CMPS
$1.52B
$981K 0.02%
+142,243
New +$867K
AAPL icon
112
Apple
AAPL
$4.89T
$903K 0.02%
3,320
+1,711
+106% +$459K
CERT icon
113
Certara
CERT
$1.17B
$876K 0.02%
99,442
+39,995
+67% +$412K
BLLN
114
BillionToOne Inc
BLLN
$5.8B
$867K 0.02%
+10,589
New +$1.07M
AMZN icon
115
Amazon
AMZN
$2.5T
$817K 0.02%
3,541
+1,729
+95% +$396K
RYTM icon
116
Rhythm Pharmaceuticals
RYTM
$7B
$803K 0.02%
7,504
-1,549
-17% -$164K
ARWR icon
117
Arrowhead Research
ARWR
$12.1B
$767K 0.01%
+11,550
New +$566K
NVDA icon
118
NVIDIA
NVDA
$5.01T
$734K 0.01%
3,933
+3,231
+460% +$601K
MLYS icon
119
Mineralys Therapeutics
MLYS
$2.35B
$719K 0.01%
19,826
-6,779
-25% -$272K
BABA icon
120
Alibaba
BABA
$269B
$689K 0.01%
+4,700
New +$765K
GOOGL icon
121
Alphabet (Google) Class A
GOOGL
$3.91T
$647K 0.01%
2,066
+984
+91% +$281K
ANET icon
122
Arista Networks
ANET
$219B
$629K 0.01%
+4,800
New +$661K
MA icon
123
Mastercard
MA
$477B
$628K 0.01%
+1,100
New +$615K
BIIB icon
124
Biogen
BIIB
$29.9B
$627K 0.01%
3,565
-648
-15% -$106K
MSFT icon
125
Microsoft
MSFT
$2.84T
$620K 0.01%
1,282
+1,079
+532% +$541K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q4 2025 Portfolio in Review

As of Q4 2025, Bellevue Group held 185 positions worth $5.28B, up 9.6% from $4.81B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Bellevue Group withdrew a net $292M in Q4 2025, closing 9 positions and reducing 83 holdings. Its most notable exit was Agios Pharmaceuticals, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Viridian Therapeutics worth $136M.

  • Bellevue Group's largest Q4 2025 buy was Viridian Therapeutics: 4,358,527 shares worth $136M.
  • Bellevue Group added most to Krystal Biotech in Q4 2025, an estimated $86.1M increase.
  • Bellevue Group's biggest Q4 2025 reduction was Incyte, cutting an estimated $139M.
  • Bellevue Group fully exited Agios Pharmaceuticals in Q4 2025, selling an estimated $149M.
  • Bellevue Group's ten largest holdings make up 49% of its $5.28B portfolio in Q4 2025.
  • Bellevue Group opened 37 new positions and closed 9 in Q4 2025.
  • Bellevue Group's portfolio value rose 9.6% quarter-over-quarter to $5.28B.

Based on Bellevue Group's 13F filing for Q4 2025, filed 17 Feb 2026.